Skip to content
developed-europe-header

Developed Europe

Sterile Focus Brands and third party manufacturing are the most material contributors to revenue in this region.
The active pharmaceutical ingredient (“API”) site in The Netherlands, supported by its satellite operation at Sioux City, in the United States supplies APIs worldwide. We provide a broad range of sterile medicines in Europe largely utilised in an acute hospital setting.

Key Countries

France
Germany
Italy
The Netherlands
United Kingdom

pic-15europe-new
  • The Developed Europe Injectable Thrombosis market was valued at
    EUR1,9 billion as at March 2020.
  • The EU5 (France, Germany, Italy, Spain, UK) propofol market was valued at
    EUR372 million as at 31 December 2019.

Source: IQVIA

STATISTICS

Number of products launched:

Nil

(2019: nil)

Average staff turnover:

10%

(2019: 9%)

Number of product recalls:

3

(2019: 4)

Number of work-related fatalities:

Nil

(2019: nil)

Number of permanent employees

2 186

June 2020

2 232

June 2019

Revenue 2020
R’million
2019 (CER)
R’million
change
%
Total 13 857 12 964 7
Regional Brands 1 784 1 905 (6)
Sterile Focus Brands 5 764 5 593 3
   Anaesthetics Brands 2 677 2 346 14
   Thrombosis Brands 3 087 3 247 (5)
Total Commercial Pharmaceuticals 7 548 7 498 1
Manufacturing 6 309 5 466 15
   FDF 681 686 (1)
   API 5 628 4 780 18

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.

Scroll To Top